Abstract
DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy for patients with myelodysplastic syndrome. New hypomethylating agents, zebularine and isothiocyanates, are in various stages of development for cancer therapy. In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer.
Keywords: Epigenetic, chromatin, DNA hypomethylation, azacitidine, decitabine, zebularine
Current Cancer Drug Targets
Title: Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Volume: 10 Issue: 5
Author(s): S. Cang, Q. Lu, Y. Ma and D. Liu
Affiliation:
Keywords: Epigenetic, chromatin, DNA hypomethylation, azacitidine, decitabine, zebularine
Abstract: DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy for patients with myelodysplastic syndrome. New hypomethylating agents, zebularine and isothiocyanates, are in various stages of development for cancer therapy. In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer.
Export Options
About this article
Cite this article as:
Cang S., Lu Q., Ma Y. and Liu D., Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517217
DOI https://dx.doi.org/10.2174/156800910791517217 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Prevention of Neointimal Hyperplasia by Local Application of Lentiviral Vectors Encoding Pin1 shRNA in Pluronic F127
Current Gene Therapy Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients
Reviews on Recent Clinical Trials A Review on Metal Nanoparticles from Medicinal Plants: Synthesis, Characterization and Applications
Nanoscience & Nanotechnology-Asia Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Radiometal Complexes in Molecular Imaging and Therapy
Current Medicinal Chemistry Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Intraperitoneal Chemotherapy as First-Line Treatment in the Management of Epithelial Ovarian Cancer
Mini-Reviews in Medicinal Chemistry Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry An Updated Review of Natural Products Intended to Prevent or Treat Oral Mucositis in Patients Undergoing Radio-Chemotherapy
Current Pharmaceutical Biotechnology Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery